Texas Biotech (TXB) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Texas Biotech (TXB)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: scaram(o)uche who wrote (798)	4/20/2001 12:19:26 PM
From: keokalani'nui	Read Replies (1) of 834

TXB only talks about Generation 1, which was OK efficacy but had some side effects--see home page. Gen 2 is a black box for the moment, but P1 results are coming. And so I await. With what happened to Actelion (btw, its drug has abstracts on PubMed), I think I'm going to get smarter soon. If possible. Gen 2 is split with ICOS, so unfortunately even if it proceeds the molecule is still controlled by marketing tyros. Wilder

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next